60 Degrees Pharmaceuticals, Inc.
$1.84
▼
-0.53%
2026-04-21 09:42:00
www.60degreespharma.com
NCM: SXTP
Explore 60 Degrees Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.69 M
Current Price
$1.84
52W High / Low
$17.68 / $1.29
Stock P/E
—
Book Value
$-5.25
Dividend Yield
—
ROCE
-220.2%
ROE
-2.01%
Face Value
—
EPS
$-11.73
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
3.28
Debt / Equity
4.52
Current Ratio
2.66
Quick Ratio
2.3
Forward P/E
-0.22
Price / Sales
3.29
Enterprise Value
$11.53 M
EV / EBITDA
-1.5
EV / Revenue
8.18
Rating
Strong Buy
Target Price
$14.1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
| 2. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 3. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 4. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 5. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 6. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 7. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.3 M | 0.44 M | 0.1 M | 0.16 M | 0.23 M | — |
| Operating Profit | -1.92 M | -2.33 M | -1.6 M | -1.91 M | -2.08 M | — |
| Net Profit | -1.44 M | -2.32 M | -1.73 M | -1.88 M | -2.05 M | — |
| EPS in Rs | -0.55 | -0.88 | -0.66 | -0.71 | -0.78 | -17.68 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.01 M | 0.61 M | 0.25 M | 0.22 M |
| Operating Profit | -7.76 M | -9.72 M | -5.15 M | -1.75 M |
| Net Profit | -7.37 M | -7.95 M | -3.77 M | -6.18 M |
| EPS in Rs | -2.79 | -3.01 | -1.43 | -2.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.37 M | 5.76 M | 7.78 M | 1.3 M |
| Total Liabilities | 1.99 M | 1.8 M | 2.99 M | 25.45 M |
| Equity | 3.46 M | 4.04 M | 4.87 M | -23.58 M |
| Current Assets | 4.9 M | 5.39 M | 7.24 M | 1.1 M |
| Current Liabilities | 1.84 M | 1.66 M | 2.84 M | 23.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.85 M | -5.65 M | -4.54 M | -1.01 M |
| Investing CF | 0.25 M | -1.89 M | -0.12 M | -0.06 M |
| Financing CF | 6.44 M | 7.05 M | 6.47 M | 1.22 M |
| Free CF | -7.07 M | -5.83 M | -4.66 M | -1.07 M |
| Capex | -0.22 M | -0.18 M | -0.12 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 139.61% | 13.6% | — | — |
| Earnings Growth % | -111.04% | 39.08% | — | — |
| Profit Margin % | -1308.01% | -1485.06% | -2769.49% | — |
| Operating Margin % | -1599.01% | -2032.78% | -784.22% | — |
| Gross Margin % | 36.67% | -87.15% | -93.71% | — |
| EBITDA Margin % | -1297.62% | -562.58% | -944.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-20 | 1:0.25 |
| 2025-02-24 | 1:0.2 |
| 2024-08-12 | 1:0.0833333 |